Business
Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025
Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife® System in the treatment of prostate cancer at multiple stages of the cancer journey. The studies, shared at the annual congress held in Vienna, Austria, indicate the system's accuracy and precision enable treatment of high-risk disease, as well as recurrent prostate cancer following prostatectomy, wi
About this update from Accuray Incorporated
[{"type":"text","content":"More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia ","length":134,"tagName":"p","attribs":{}},{"type":"text","content":"MADISON, Wis., May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife® System in the treatment of prostate cancer at multiple stages of the cancer journey. The studies, shared at the annual congress held in Vienna, Austria, indicate the system's accuracy and precision enable treatment of high-risk disease, as well as recurrent prostate cancer following prostatectomy, with stereotactic body radiation therapy (SBRT), expanding access to a non-invasive, short course of care to more men.","length":667,"tagName":"p"},{"type":"image","alt":"Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)","displaySize":"","headline":null,"caption":"Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":63,"url":"https://media.zenfs.com/en/prnewswire.com/8d559378b9aa528dfc02aa2f91aff376"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OyBvlePxn41ydvo8OkT8HQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/8d559378b9aa528dfc02aa2f91aff376","width":400,"height":63}},"href":"https://mma.prnewswire.com/media/320376/accuray_incorporated_logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""At this year's ESTRO meeting important analyses of real-world evidence (RWE) underscored the benefits of our unique robotic and helical platforms, reaffirming their use as patients' primary care option or along with other modalities such as surgery, chemotherapy or immunotherapy. Stand out studies focused on the company's CyberKnife System for the treatment of prostate cancer, building on a robust body of clinical data supporting its use and confirming the durability and quality of life after 10 years post-treatment. We're grateful to the clinicians who continue to evaluate our technologies and advance personalized and precise care of patients throu...